Differentiation of δ, μ, and κ opioid receptor agonists based on pharmacophore development and computed physicochemical properties

Compounds that bind with significant affinity to the opioid receptor types, δ, μ, and κ, with different combinations of activation and inhibition at these three receptors could be promising behaviorally selective agents. Working on this hypothesis, the chemical moieties common to three different sets of opioid receptor agonists with significant affinity for each of the three receptor types δ, μ, or κ were identified. Using a distance analysis approach, common geometric arrangements of these chemical moieties were found for selected δ, μ, or κ opioid agonists. The chemical and geometric commonalities among agonists at each opioid receptor type were then compared with a non-specific opioid recognition pharmacophore recently developed. The comparison provided identification of the additional requirements for activation of δ, μ, and κ opioid receptors. The distance analysis approach was able to clearly discriminate κ-agonists, while global molecular properties for all compounds were calculated to identify additional requirements for activation of δ and μ receptors. Comparisons of the combined geometric and physicochemical properties calculated for each of the three sets of agonists allowed the determination of unique requirements for activation of each of the three opioid receptors. These results can be used to improve the activation selectivity of known opioid agonists and as a guide for the identification of novel selective opioid ligands with potential therapeutic usefulness.

[1]  Michal Hušák,et al.  The Crystal and Molecular Structure of Butorphanol Hydrogen Tartrate , 1994 .

[2]  Ping Huang,et al.  Development of a common 3D pharmacophore for δ-opioid recognition from peptides and non-peptides using a novel computer program , 1997, J. Comput. Aided Mol. Des..

[3]  Lei Yu,et al.  Molecular cloning and functional expression of a mu opioid receptor from rat brain , 1994, Regulatory Peptides.

[4]  Gilda H. Loew,et al.  Thermodynamics of ligand binding to the cloned δ-opioid receptor , 1996 .

[5]  H. Loh,et al.  Regulation of opioid receptor activities. , 1999, The Journal of pharmacology and experimental therapeutics.

[6]  A Ulloa-Aguirre,et al.  Structure-activity relationships of G protein-coupled receptors. , 1999, Archives of medical research.

[7]  A. Kastin,et al.  Opiate tolerance and dependence: receptors, G-proteins, and antiopiates , 1998, Peptides.

[8]  Judith L. Flippen-Anderson,et al.  X-Ray crystal structures of potent opioid receptor ligands: etonitazene, cis-(+)-3-methylfentanyl, etorphine, diprenorphine, and buprenorphine , 1994 .

[9]  A. Verloop,et al.  Development and Application of New Steric Substituent Parameters in Drug Design , 1976 .

[10]  P. Pascoe,et al.  Perioperative pain management. , 2000, The Veterinary clinics of North America. Small animal practice.

[11]  M. Nishi,et al.  Primary structures and expression from cDNAs of rat opioid receptor δ‐and μ‐subtypes , 1993 .

[12]  D. Ferguson,et al.  Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor. , 2000, Journal of medicinal chemistry.

[13]  L. Bare,et al.  Isolation of a Human κ Opioid Receptor cDNA from Placenta , 1994 .

[14]  Marta Filizola,et al.  3D modeling, ligand binding and activation studies of the cloned mouse δ, μ and κ opioid receptors , 1999 .

[15]  Jonas Boström,et al.  Conformational energy penalties of protein-bound ligands , 1998, J. Comput. Aided Mol. Des..

[16]  G. Uhl,et al.  Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. , 1994, FEBS letters.

[17]  A. Lomize,et al.  Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints. , 1998, Biophysical journal.

[18]  Lakshmi A Devi,et al.  Opioids and Their Complicated Receptor Complexes , 2000, Neuropsychopharmacology.

[19]  Henry I. Mosberg Complementarity of δ opioid ligand pharmacophore and receptor models , 1999 .

[20]  Marta Filizola,et al.  Molecular determinants of non-specific recognition of δ, μ, and κ opioid receptors , 2001 .

[21]  H. Villar,et al.  Strategies for Indirect Computer-Aided Drug Design , 1993, Pharmaceutical Research.

[22]  E Bye,et al.  Crystal structures of synthetic analgetics. V. Dextromoramide. , 1976, Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry.

[23]  Hugo O. Villar,et al.  Quantum mechanical parametrization of a conformationally dependent hydrophobic index , 1992 .

[24]  H Weinstein,et al.  Comparative modeling and molecular dynamics studies of the delta, kappa and mu opioid receptors. , 1997, Protein engineering.

[25]  R. Edwards,et al.  Cloning of a delta opioid receptor by functional expression. , 1992, Science.

[26]  G H Loew,et al.  Evidence for mu1-opioid receptor involvement in fentanyl-mediated respiratory depression. , 1996, European journal of pharmacology.

[27]  Marta Filizola,et al.  Molecular modeling study of the differential ligand–receptor interaction at the μ, δ and κ opioid receptors , 1999, J. Comput. Aided Mol. Des..

[28]  H. Villar,et al.  Atom based parametrization for a conformationally dependent hydrophobic index , 1991 .

[29]  V. Ananthanarayanan,et al.  Homology models of mu-opioid receptor with organic and inorganic cations at conserved aspartates in the second and third transmembrane domains. , 2000, Archives of biochemistry and biophysics.

[30]  B. Kieffer,et al.  A molecular basis for opiate action. , 1998, Essays in biochemistry.

[31]  Juan J. Perez,et al.  Characterization of the bioactive form of linear peptide antagonists at the δ‐opioid receptor , 1996 .

[32]  C L Brooks,et al.  Do active site conformations of small ligands correspond to low free-energy solution structures? , 1998, Journal of computer-aided molecular design.

[33]  U. Gether Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. , 2000, Endocrine reviews.